Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02129660 · ClinicalTrials.gov registry record · Phase 2
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
A Phase 2 study of Hyperhidrosis, sponsored by Journey Medical Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 15
- Study locations
NCT02129660: Completed Phase 2 study of Hyperhidrosis, sponsored by Journey Medical Corporation.
NCT02129660 is a Phase 2 study of Hyperhidrosis that has completed, run by Journey Medical Corporation. The registered enrollment target is 105 participants, above the 86-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (22% higher). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02129660, a Phase 2 study of Hyperhidrosis, has completed, sponsored by Journey Medical Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks followed by a 2-week post-dose period.
Primary Outcome
HDSS is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities. 1 (Best), 2, 3, 4 (Worst)
Conditions Studied
Interventions
- OTHER Vehicle
- DRUG Dose 1 of glycopyrrolate, 2.0% QD
- DRUG Dose 2 of glycopyrrolate, 3.0% QD
- DRUG Dose 1 of glycopyrronium, 2.5% QD
- DRUG Dose 2 of glycopyrronium, 3.75% QD
Study Locations (15)
Washington
- Dermatology Associates - Seattle
- Women's Clinical Research Center - Seattle
- Premier Clinical Research - Spokane
California
- California Dermatology & Clinical Research Institute - Encinitas
- Center For Dermatology Clinical Research - Fremont
Florida
- Olympian Clinical Research - Tampa
- Kenneth R. Beer MD - West Palm Beach
Indiana
- Shideler Clinical Research Center - Carmel
Missouri
- Saint Louis University Dermatology - St Louis
Ohio
- Haber Dermatology and Cosmetic Surgery - Beachwood
Tennessee
- Rivergate Dermatology Clinical Research Center, PLLC - Goodlettsville
Texas
- DermResearch, Inc - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT02129660 record still lists
NCT02129660 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 86-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Hyperhidrosis appearing as the primary indexed condition, and to 5 interventions - of which Vehicle is the first listed.
NCT02129660 lists 15 locations in 11 states (Washington, California, Florida).
Frequently Asked Questions
What is clinical trial NCT02129660 about?
NCT02129660 is a clinical study titled "Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis". The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks followed by a 2-week post-dose period.
What is the current status of trial NCT02129660?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2014-04. Estimated completion is 2015-01.
What conditions does trial NCT02129660 study?
This clinical trial studies the following conditions: Hyperhidrosis.
What interventions are being tested in trial NCT02129660?
The interventions under investigation include: Vehicle (OTHER), Dose 1 of glycopyrrolate, 2.0% QD (DRUG), Dose 2 of glycopyrrolate, 3.0% QD (DRUG), Dose 1 of glycopyrronium, 2.5% QD (DRUG), Dose 2 of glycopyrronium, 3.75% QD (DRUG).
Who is sponsoring clinical trial NCT02129660?
This trial is sponsored by Journey Medical Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02129660 being conducted?
This trial has 15 study locations across California, Florida, Indiana, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02129660's enrollment target sits among peer trials
105 4th of 8 higher than 5 of 8 other Hyperhidrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperhidrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
COMPLETED · Phase 2
-
An Open Label Study for Palmar Hyperhydrosis
COMPLETED · Phase 2
-
Botulinum Toxin Therapy in Hidradenitis Suppurativa
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia